한글목차

DKN-01은 Dickkopf-1(DKK1) 단백질에 결합하여 그 활성을 억제하여 종양 미세 환경에서 자연 면역 체계의 활성화와 항 종양 활성을 가져오는 인간화 단일 클론 항체이며, DKK1은 Wnt/β-catenin 및 PI3 kinase/ACT 신호 전달 경로를 조절하고, 골수 유래 억제 세포의 활성을 증가시키고, 종양 세포의 NK 세포 리간드를 하향 조절함으로써 종양 세포의 신호 전달 및 면역 억제 종양 미세 환경을 매개하는 데 중요한 역할을 합니다. 이 약은 2027년까지 시장에 진입할 것으로 예상됩니다.

앞으로 몇 년동안 난소암 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 회사는 질병을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, DKN-01의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 난소암에 대한 다른 신흥 제품들이 DKN-01과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 난소암 치료제 DKN-01 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 난소암 DKN-01개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 DKN-01 시장 평가

• 난소암 치료제 DKN-01 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 난소암 치료제 DKN-01 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"DKN-01 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about DKN-01 for ovarian cancer in the seven major markets. A detailed picture of the DKN-01 for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the DKN-01 for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DKN-01 market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.

Drug Summary:

DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, leading to the activation of the innate immune system in the tumor microenvironment and antitumor activity. DKK1 modulates the Wnt/beta-catenin and PI3kinase/AKT signaling pathways, which have an important role in tumor cell signaling and mediating an immunosuppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells. The drug is expected to enter the market by 2027.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DKN-01 description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
• Elaborated details on DKN-01 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DKN-01 research and development activities in ovarian cancer across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DKN-01.
• The report contains forecasted sales of DKN-01 for ovarian cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
• The report also features the SWOT analysis with analyst views for DKN-01 in ovarian cancer.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DKN-01 Analytical Perspective by DelveInsight

• In-depth DKN-01 Market Assessment

This report provides a detailed market assessment of DKN-01 for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• DKN-01 Clinical Assessment

The report provides the clinical trials information of DKN-01 for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DKN-01 dominance.
• Other emerging products for ovarian cancer are expected to give tough market competition to DKN-01 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DKN-01 in ovarian cancer.
• Our in-depth analysis of the forecasted sales data of DKN-01 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DKN-01 in ovarian cancer.

Key Questions:

• What is the product type, route of administration and mechanism of action of DKN-01?
• What is the clinical trial status of the study related to DKN-01 in ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DKN-01 development?
• What are the key designations that have been granted to DKN-01 for ovarian cancer?
• What is the forecasted market scenario of DKN-01 for ovarian cancer?
• What are the forecasted sales of DKN-01 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to DKN-01 for ovarian cancer?
• Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?

Table of Contents

1. Report Introduction

2. DKN-01 Overview in ovarian cancer

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. DKN-01 Market Assessment

• 5.1. Market Outlook of DKN-01 in ovarian cancer
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of DKN-01 in the 7MM for ovarian cancer
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of DKN-01 in the United States for ovarian cancer
  • 5.3.2. Market Size of DKN-01 in Germany for ovarian cancer
  • 5.3.3. Market Size of DKN-01 in France for ovarian cancer
  • 5.3.4. Market Size of DKN-01 in Italy for ovarian cancer
  • 5.3.5. Market Size of DKN-01 in Spain for ovarian cancer
  • 5.3.6. Market Size of DKN-01 in the United Kingdom for ovarian cancer
  • 5.3.7. Market Size of DKN-01 in Japan for ovarian cancer

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options